BYS10, a novel selective RET inhibitor, exhibits potent antitumor activity in preclinical models
Collectively, BYS10 represents a novel, highly selective RET inhibitor with superior <i>in vitro</i> and <i>in vivo</i> activity against multiple RET alterations compared to Selpercatinib. Its recent Investigational New Drug (IND) approvals from the FDA and NMPA underscore its therapeutic potential for RET-driven malignancies.
Authors
- Rong Guo (ORCID: https://orcid.org/0000-0002-4005-5992)
- Yiman Chen (ORCID: https://orcid.org/0000-0001-6809-4291)
- Yingxia Bao
- Tony Chieh‐Ting Huang (ORCID: https://orcid.org/0000-0003-0462-7786)
- Jiaji Zhao
- Zhoufan Xie
- Jinhai Deng (ORCID: https://orcid.org/0000-0002-2899-5332)
- Fei Qin (ORCID: https://orcid.org/0000-0001-6475-2306)
- Zhibo Luo (ORCID: https://orcid.org/0009-0008-3047-3200)
- Lin Wang (ORCID: https://orcid.org/0000-0002-6449-4930)
- Jiansong Wang (ORCID: https://orcid.org/0000-0001-5451-5358)
Institutions
- Guangdong Pharmaceutical University (CN)
- Beijing VDJBio (China) (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.3389/fphar.2025.1670140
- Primary Topic
- Mechanisms of cancer metastasis
- Type
- article
- Field-Weighted Citation Impact
- 0.00